Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

ACIP recommends extending interval for two-dose series and adding three-dose series in accordance with FDA label ...

The approval was based on data from 2 randomized, double-blind, placebo-controlled trials, ARCADIA 1 and ARCADIA 2.

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

Highest percentage of patients with HBsAg loss after end of treatment for those receiving xalnesiran + immunomodulator ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.

The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.

Interim data from a phase 3 study evaluating tecovirimat for the treatment of human mpox virus showed the antiviral did not improve time to lesion resolution compared with placebo.

The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.

A higher risk of liver transplant and death was observed in Ocaliva-treated patients vs those who received placebo.

The FDA is expected to decide on treatments for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine.

Findings seen among children and adolescents with type 1 diabetes and nonoptimal control with traditional treatment ...